This review summarizes the pharmacological properties and clinical data of antiplatelet and anticoagulation therapies to optimize the balance between thrombosis and bleeding during PCI.
May guide antiplatelet/anticoagulant selection during PCI; extends prior syntheses but leaves optimal regimens open for prospective trials.
Pharmacotherapy for percutaneous coronary interventions is essential to optimize the balance between thrombosis and bleeding. Currently, choices abound for the selection of antiplatelet and anticoagulation therapies during percutaneous intervention (PCI). This review article discusses the mechanisms, pharmacokinetics/dynamics, and clinical data behind the various pharmacotherapies including; aspirin, thienopyridines, glycoprotein IIb/IIIa inhibitors, vorapaxar, heparin, direct thrombin inhibitors, and factor Xa inhibitors.
No takes yet. Share an insight, caveat, or question.
Basman et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: